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Background: Real world evidence about antipsychotics focuses on rehospitalization.
Modeling the time course of pharmacotherapy would show patients’ adherence
to medications and physicians’ adherence to medication guidelines. We aimed to
calculate the cumulative time spent in second generation antipsychotics (SGAs), gaps,
antipsychotic polypharmacy, and clozapine in discharged schizophrenia patients.
Methods: Hospitalization and pharmacy dispensing data from 2008–2018 in Manitoba,
Saskatchewan, and British Columbia were linked and an electronic cohort (N = 2,997)
was created (mean follow-up: 49 months, SD = 38). Cohort members were required
to have a minimum of 6 weeks medicated with aripiprazole, olanzapine, paliperidone,
quetiapine, risperidone, or ziprasidone.
Results: The multistate model predicted that schizophrenia patients accumulated 44
months in SGA monotherapy, 4 months in polypharmacy, 11 months in medication gaps
and 17 days in clozapine over a 5-year period. The majority of transitions were between
SGA and medication gap. Accumulated time in medication gaps was seven times as
much as in clozapine. Each 10% delay in SGA initiation post-discharge was associated
with a 2, 1, and 6% higher risk for polypharmacy (95% CI: 1.01–1.02), gap (95% CI:
1.01–1.01), and clozapine (95% CI: 1.04–1.08), respectively.
Interpretation: Schizophrenia patients accumulated more time unmedicated and in
polypharmacy compared to clozapine. Either treatment guidelines for schizophrenia are
not followed, or real-world challenges hamper their implementation.
Keywords: polypharmacy, real world evidence (RWE), treatment guideline implementation, antipsychotics,
schizophenia, adherence - compliance - persistance

INTRODUCTION
Pharmacotherapy remains the mainstay of treatment for schizophrenia (1). Yet with few specific
treatment guidelines, prescribers necessarily rely upon clinical acumen in collaboration with
patients. High-quality evidence for first-episode psychosis is even scarcer, as ethical considerations
discourage placebo-controlled trials (1).

1

June 2022 | Volume 13 | Article 917361

Peters et al.

Second Generation Antipsychotics in Canada

honorarium. Our research was conducted in accordance with the
Helsinki declaration of respect for patients.

An exception is clozapine for treatment-resistant
schizophrenia, which continues to be strongly supported
(1, 2). There is also evidence to suggest clozapine for patients
with prominent negative symptoms (3, 4), aggression (5),
suicidality (6), and comorbid substance use (7). However,
clozapine is prescribed less frequently than would be expected
by its indications (2, 8, 9), suggesting either an implementation
failure or treatment guidelines that overestimate real-world
effectiveness. Real world studies on clozapine tend to focus on
more severely ill patients, so it is hard to estimate at what point it
is introduced in treatment (10).
According to the Maudsley Treatment Review and Assessment
Team (TREAT), various practical considerations contribute to
the under-prescribing (or delayed initiation) of clozapine (11).
Among these are: identifying treatment refractory patients,
ascertaining if previous treatment was adequate, establishing the
patient’s willingness to engage, and weighing the risks vs. benefits
of clozapine for each patient (11). These steps require close
coordination among different care providers. Patients on their
part may refuse blood tests, and this can delay clozapine initiation
(12). There are also barriers on the side of clinicians such as
fear of serious side-effects, the burden of constant monitoring,
and a self-reported lack of competence (12). Among patients
who have agreed to clozapine treatment, several reasons are
given for discontinuing: intolerable side effects, non-compliance
with blood monitoring, and dysfunctional beliefs about clozapine
treatment (13).
Advanced statistical techniques such as network meta-analysis
have recently been used to rank large numbers of antipsychotics
in terms of efficacy and tolerability/safety with data from clinical
trials (3, 14). It remains less clear if these rankings inform clinical
practice. The extensive selection criteria found in most trials is a
constraint to the generalizability of the findings, thereby making
it necessary to examine real-world data (15).
Here, we analyzed prescription and hospitalization data for
patients with schizophrenia from three Canadian provinces, with
the following objectives:

Data Sources
This was a retrospective study of administrative data about
hospitalizations and pharmacy dispensing data in British
Columbia, Manitoba, and Saskatchewan from 2008–2018.
Hospitalization data consisted of emergency room visits
captured in the National Ambulatory Care Reporting System
(NACRS) and inpatient stays in the Discharge Abstract Database
(DAD). Psychotropic medications were obtained from the
National Prescription Drug Utilization Information System
Database (NPDUIS)—a Canada-wide register of publicly funded
medications dispensed by pharmacies in the community. Despite
this national scope, the provincial (territorial) programs only
cover low income people and seniors, except for the provinces
in this study. Hospitalization and medication files were provided
separately by the Canadian Institute of Health Information
(CIHI). We linked these files using a unique person identifier
provided by CIHI. Our data captured all mental-health related
visits and >85% of all psychotropic medications. The exceptions
were medications used in hospital and those covered by federal
programs. Also, patients emigrating from the three Canadian
provinces may have had their records truncated.

Cohort Formation
Patients in an electronic register differ importantly from those
enrolled in randomized clinical trials. Trial participants satisfy
explicit inclusion and exclusion criteria, thereby ensuring that
they are a homogenous group. In contrast, patients in our
registries only had the common characteristic of visiting the
hospital for a mental condition and obtaining medications from
a pharmacy. As such, our first task was to identify a moreor-less homogenous cohort in diagnosis and severity of illness.
Accordingly, we formed a cohort of patients using their first
hospital visit as an index date and applied the following criteria:
1. Schizophrenia diagnosis (ICD-10 codes: F20.1–F20.9).
2. Adult onset (i.e., aged 19+ at index hospital visit, allowing
for the possibility that the true illness onset may have been 18
or younger).
3. Medicated for at least 6 weeks with one of the following SGAs
after the hospital visit: aripiprazole, olanzapine, paliperidone,
quetiapine, risperidone, and ziprasidone.

1. Estimate the dispensing frequency of several secondgeneration antipsychotics (SGA).
2. Estimate the prevalence of (i) initial SGA, (ii) polypharmacy,
(iii) unmedicated treatment gaps, (iv) clozapine, (v)
rehospitalization, as well as the cumulative time spent and
total visits (or returns) to each state.
3. Calculate the probability of transitions between states and
how these are affected by socio-demographic characteristics.

We further applied the following criteria in order to capture
patients with less serious presentations (i.e., excluding resistant
or seriously ill patients):
4. First hospital visit did not contain an ICD code for intentional
self-injury or poisoning (X60–X84).
5. Patient was not already on SGA polypharmacy (i.e., not
medication resistant).
6. Patient was not already on clozapine or a less-commonly
dispensed SGA.

METHODS
Patient Involvement
One-on-one interviews with six persons with schizophrenia and
a mental health nurse were held to elicit their lived experience
and inform our research questions. After obtaining the results,
one patient provided feedback. Recruiting patients, a vulnerable
group, was approved by the university ethics board and all
participants gave their informed consent and received a small
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Applying these criteria to the 7,897 patients with a
schizophrenia diagnosis at the index visit yielded a cohort of
2,997 people (Figure 1). The socio-demographic characteristics
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FIGURE 1 | Strobe diagram of a cohort of schizophrenia patients and selection criteria.

had to have spent at least 6 weeks on SGA monotherapy.
This was based on the guideline that response to treatment
(if it happens at all) can typically be observed within the
first 6–8 weeks (16). The terminal state was rehospitalization.
From SGA monotherapy, each person could progress to any
of the transient States (2–4), with repeated visits. Follow-up
ended when a person was rehospitalized, the person ran out
of data, or the cut-off of CIHI data was reached. In the
latter two cases, the person was considered lost to follow-up.
The assignment of states, especially gaps and polypharmacy
(discussed below), was greatly facilitated by the Stata newspell
package (17).

of these people at their index visit are summarized in Table 1.
For each cohort member, SGA refills (and rehospitalization, if
applicable) were followed until February 2019 or loss to followup, whichever came first. Cohort members had a mean follow-up
time of 49 months (SD = 38) and this did not differ by province.

Classification of Treatment States
Each person in the cohort had a longitudinal record of
hospitalizations and medication refills. We sorted these records
from earliest to most recent. We were interested in four
transient states: (1) initial antipsychotic, (2) polypharmacy, (3)
unmedicated (treatment gaps), and (4) clozapine. Each person

Frontiers in Psychiatry | www.frontiersin.org
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Definition of Polypharmacy, Clozapine, and
Rehospitalization States

pipotiazine, prochlorperazine, sulpiride, trifluoroperazine, and
zuclopenthixol. If clozapine overlapped with another medication,
this period was assigned to clozapine. Rehospitalization in this
study was defined as a hospital visit associated with a mental
health condition (ICD F code) or self-harm (ICD X60–X84).

A patient was assigned to the polypharmacy state if two or
more psychotropic medications overlapped during follow-up.
These psychotropic medications were not limited to the six
SGAs in State 1 but included asenapine, chlorpromazine,
flupentixol, fluphenazine, haloperidol, levomepromazine,
lithium, loxapine, lurasidone, perphenazine, pimozide,

Treatment Gap Calculation
Since all hospitalizations and all psychotropic refills were
captured, the follow-up period for each person could be classified
into the five states above, subject to the limitation that we did not
have quantity and dose at each refill. For this reason, we could not
be sure that a person possessed adequate medication during the
period between refills, or if there was a gap for which a person was
unmedicated. People filled prescriptions at irregular intervals.
According to a paper about estimating medication adherence,
the grace period between consecutive refills, in various studies,
ranges from 15 to 120 days (18). Based on typical prescribing
practices, we fixed the grace period at 30 days. Treatment gap was
therefore operationally defined as the period starting from day 31
to the date of the subsequent refill (Supplementary Figure S1).

TABLE 1 | Demographic profile of schizophrenia patients at index hospitalization
in three Canadian provinces.
Variable

Manitoba

Saskatchewan

British Columbia

N

609 (20)

272 (9)

2,116 (71)

Mean age (SD)

48 (19)

51 (19)

44 (17)

Sex
Male (%)

367 (60)

156 (57)

1,284 (61)

Female (%)

242 (40)

116 (43)

832 (39)

Initial SGA
Aripiprazole (%)

22 (4)

11 (4)

167 (8)

Olanzapine (%)

230 (38)

59 (22)

558 (26)
218 (10)

Paliperidone (%)

15 (2)

11 (4)

Quetiapine (%)

115 (19)

73 (27)

336 (16)

Analysis

Risperidone (%)

220 (36)

107 (39)

800 (38)

Ziprasidone (%)

7(1)

11 (4)

37 (2)

Rural, remote, or
unclassified area of
residence

90 (15)

46 (17)

177 (8)

Urban

519 (85)

226 (83)

1,939 (92)

Mean days to first SGA
dispense after discharge
from index
hospitalization (SD)

45 (144)

54 (209)

37 (131)

Mean months to first
clozapine dispense (SD)*

30 (34)

13 (14)

41 (28)

We fitted a multistate survival model (MSM) using the R
package msm (19). This was based on several considerations:
(1) The msm package is capable of handling continuous (vs.
discrete) time transitions. (2) It handles intermittently observed
events (i.e., refills). (3) The msm package allows for cyclic
transitions. A MSM is comparable to a simple survival model
except that the hazard is calculated for transitions between
transient states (i.e., SGA, polypharmacy, gap, and clozapine) and
from transient states to the absorbing state (rehospitalization).
For a schematic of the states and transitions in our model,
please refer to Supplementary Figure S2. We had four candidate
predictor variables: age at index hospitalization, the interval
between hospital discharge and the first pharmacy dispense date,
rural/remote/unclassified area of residence vs. urban, and gender.

Residence

*Calculated only for 57 people who were ever put on clozapine; Number (% of total
patients): Manitoba: 9 (1.5), Saskatchewan: 3 (1.1), B.C: 45 (2.1).

TABLE 2 | Number (%) of patients in a stage by follow-up time (months). The denominator is the total number of patients remaining in the cohort at a given month.
Follow-up time
in months

SGA

Polypharmacy

Medication Gap

Clozapine

Rehospitalized

0

2,997 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

6

2,067 (79.5)

96 (3.7)

430 (16.5)

4 (0.2)

4 (0.2)

12

1,757 (75.8)

95 (4.1)

446 (19.2)

7 (0.3)

12 (0.5)

18

1,543 (73.0)

116 (5.5)

423 (20.0)

16 (0.8)

17 (0.8)

24

1,394 (72.3)

108 (5.6)

388 (20.1)

18 (0.9)

21 (1.1)

30

1,240 (71.3)

108 (6.2)

347 (19.9)

19 (1.1)

26 (1.5)

36

1,113 (70.3)

120 (7.6)

303 (19.1)

16 (1.0)

32 (2.0)

42

995 (69.5)

100 (7.0)

283 (19.8)

19 (1.3)

35 (2.4)

48

874 (67.6)

105 (8.1)

256 (19.8)

19 (1.5)

39 (3.0)

54

817 (69.1)

83 (7.0)

218 (18.4)

21 (1.8)

44 (3.7)

60

740 (69.2)

73 (6.8)

184 (17.2)

23 (2.2)

49 (4.6)
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a 73% chance of remaining on clozapine. The probability
of rehospitalization at 3 months was close to zero
(Table 3).
The transition probabilities including loss to follow-up for
the entire follow-up period is depicted in Supplement Figure S3.
Over the entire follow-up period, only 57 patients (1.9%) ever
received clozapine and 64 people (2.1%) were rehospitalized.

State Prevalence Up to 60 Months
As Table 2 shows, the proportion of schizophrenia patients
who were on an SGA was close to 70% at up to 5
years. However, at any single time except at baseline, 16–
20% of patients had a gap in treatment and 5–7% were on
polypharmacy. The total proportion of patients who received
clozapine (whether by itself or with another antipsychotic) never
reached 3% over the entire follow-up (n = 57 people). Close
to 5% of remaining cohort members were rehospitalized at
5 years.
Over a 5-year (60-month) period, the accumulated time
spent in each of the states were: 44 months in initial SGA,
4 months in polypharmacy, 11 months in medication gaps,
and 17 days in clozapine. On average, patients had 10
spells of SGA monotherapy, 1 spell of polypharmacy, 10
untreated spells and <1 clozapine spell. SGA monotherapy
and gaps tend to cycle back-and-forth as shown in
Supplementary Figure S3.

Effect of Socio-Demographic Covariates
on Transitions From SGA
Here we focus on how socio-demographic characteristics modify
the transitions from SGA, since this is the initial state. See
Supplementary Table S1 for the complete results. Each 10%
increase after age 19 represented a 3, 2, and 7% risk reduction
for polypharmacy, gap, and clozapine, respectively. Each 10%
delay in first SGA dispense after discharge was associated with a
2, 1, and 6% higher risk for polypharmacy, gap, and clozapine,
respectively. Living in a non-urban area was associated with
a 33% lower risk of polypharmacy, a 22% higher risk of a
medication gap, and 27% lower risk of being treated with
clozapine. Female patients, compared to males had a 20% higher
risk of transitioning to polypharmacy from an initial SGA.
Female patients on polypharmacy were 88% more likely to have a
medication gap. None of the variables predicted rehospitalization
from any state.

Transition Probabilities Between States
At 3 months, there was an 18% percent chance of a
gap in treatment given that one was on an SGA. Given
that a patient has a medication gap, returning to an
SGA was most likely but there was a 22% chance of
continuing to be unmedicated. People on clozapine had

TABLE 3 | Probability of transitioning to (remaining in) a state from a given state at 3 months.
From / To

SGA

Polypharmacy

Gap

Clozapine

Rehospitalized

SGA

78

4

18

0

0

Polypharmacy

41

46

12

0

0

Gap

72

5

22

0

0

Clozapine

16

1

10

73

0

Rehospitalized

0

0

0

0

1

Cell entries are percentages.

TABLE 4 | Hazard ratios (95% CI) on selected transitions for four covariates.
From:

To:

Index Age (each 10 pct
increase from 19 years)

Initial Medication Delay (each
10 percent increase from
discharge)

Rural/Remote/
Unclassified vs. Urban
(reference)

Female vs.
Male (reference)

SGA

Polypharmacy

0.97 (0.96–0.97)*

1.02 (1.01–1.02)*

0.67 (0.55–0.81)*

1.20 (1.08–1.32)*

SGA

Gap

0.98 (0.98–0.98)*

1.01 (1.01–1.01)*

1.22 (1.16–1.27)*

0.99 (0.96–1.02)
n.s.

SGA

Clozapine

0.93 (0.91–0.95)*

1.06 (1.04–1.08)*

0.73 (0.26–2.06)
n.s

0.72 (0.36–1.44)
n.s.

Polypharmacy

Gap

0.98 (0.97–0.98)*

1.00 (1.00–1.00)
n.s.

1.77 (1.42–2.20)*

1.88 (1.63–2.17)*

Polypharmacy

Clozapine

0.93 (0.89–0.97)*

1.03 (1.00–1.07)*

0.93 (0.14–6.11)
n.s.

1.21 (0.40–3.63)
n.s.

Gap

Clozapine

0.97 (0.96–0.98)*

1.04 (1.04–1.05)*

0.40 (0.19–0.85)*

Not entered

The two left columns represent the outcome, third to sixth columns are predictors that modify the baseline hazard. Predictor variables are entered simultaneously. Asterisk (*) indicates
significance at p = 0.05.
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treatment may have also contributed to underutilization (12, 34).
The three provinces varied significantly with regard to clozapine
initiation, with British Columbia waiting more than 3 years on
average. By comparison, a study of outpatient schizophrenia
patients in Manitoba reported that clozapine was initiated at 8.9
years for males and 7.7 years for females, on average (35). Twothirds of them had been on 3 or more antipsychotics before
the switch to clozapine (35). Delayed initiation of clozapine
treatment—perhaps by lingering in mono- or polypharmacy—
tends to reduce its efficacy (36).
With evidence-based guidelines being recommendatory, they
cannot compel physicians and patients to use clozapine.
However, a softer approach that eases administrative burden,
provides logistical support, and alleviates patient and clinician
concerns has been recommended (37). There is a debate
about the ethics of offering monetary rewards for adherence
to medications, and a few randomized control studies have
been undertaken (38, 39). But the possibility that such an
incentive is tantamount to coercion has made it a contentious
topic (40).
The finding that older people were at lower risk of
polypharmacy, unmedicated periods, and clozapine could mean
that they had later onset of the disease. Younger age of
onset tends to be associated with a worse prognosis (41). The
finding that delay to the first pharmacy claim from hospital
discharge increases the risk for polypharmacy, unmedicated
periods, and clozapine treatment has implications for the
provision of health services. Transitioning from hospital to
the community is known to be a vulnerable period in which
medication compliance is paramount (42, 43). The use of depot
antipsychotics and intensive community treatment programs
may improve adherence and prognosis (44–46).
Female patients had higher risk of polypharmacy. Similar
results have been reported elsewhere (28, 47, 48) but not
invariably (49, 50). Schizophrenia has earlier onset in men than
in women and earlier onset is associated with a more severe
course of illness (5). Some have reported that women are more
adherent to treatment than men (5–7), so we are unsure if this
finding reflects a gender difference per se or confounding by
other variables.
Our findings are subject to several limitations. We did
not know the true age of schizophrenia onset and used age
at index hospitalization as a proxy. Given the mean age at
index hospitalization (>40 years), it is highly improbable that
patients in the cohort were first-onset cases. Since they probably
lived with schizophrenia for a decade or more, it is more
surprising that clozapine was dispensed to so few and so late
in the treatment. Unfortunately, the data cannot distinguish
if this is a result of under-prescribing or patients refusing to
accept clozapine medication—something that needs to be further
studied. Our data sources did not contain clinical notes and
symptoms, so we did not have indications for the antipsychotic
prescriptions, and the reasons for polypharmacy. Likewise, we
could not examine the effect of gaps and polypharmacy on
symptoms. Some periods classified as polypharmacy may have
been gradual transitions from one SGA to another. Earlier
Canadian studies have estimated the prevalence of polypharmacy

We had two main findings: (i) schizophrenia patients
accumulated substantial periods without medication (treatment
gaps), and (ii) patients are on polypharmacy 7 times as long as
they are on clozapine.
Although we did not have access to the reasons for treatment
gaps, we offer two possibilities. First, patients may have
recovered from their illness so as not to require medication, but
relapsed sometime later. Up to 20% of schizophrenia patients
only experience a single episode as noted in the Canadian
Schizophrenia Guidelines (1). This is also consistent with
unmedicated rates in naturalistic longitudinal studies in the US
(20) and Finland (21). In these studies, ongoing medication was
associated with disease severity, and most of the unmedicated
patients were clinically stable (20, 21). Therefore, some treatment
gaps may reflect periods of recovery and prudent prescribing on
the part of physicians.
Alternatively, patients may have needed medications but
stopped taking them because of tolerability, logistical, or financial
reasons. This fits with the 22% higher risk of treatment gaps
among non-urban dwellers from an initial SGA and a 77%
higher risk of a gap from polypharmacy (Table 4). Adherence
to medications is influenced by patient insight into their illness,
perceived efficacy of the medication, family support, and the
availability of case managers (22, 23). Patients in non-urban
areas may have more limited contact with physicians, community
health managers, and health services in general.
Regarding affordability, it is estimated that 10% of Canadians
cannot afford out-of-pocket medication expenses (24). Up to
80% of people with schizophrenia are unemployed (25), so it
is possible that some medication gaps are a result of poverty.
Unlike universal healthcare coverage, prescription medications
are left for provincial governments to decide (26). According to
the schizophrenia patients we interviewed, affordability was not
a problem because clozapine was paid for by the Saskatchewan
provincial government. However, they were generally unable to
join the job market—even if they wanted—because their income
would count against what they receive from the government.
Although the prevalence of polypharmacy was lower than
other studies (27, 28), patients in this cohort were still 7 times
as likely to be on polypharmacy as on clozapine. This likely
reflects the extent that clozapine is underutilized. Notably, a
Canadian study noted that polypharmacy is more prevalent
than any antipsychotic monotherapy (29). In the US, <5% of
schizophrenia patients were treated with clozapine in 2008 (30)—
still higher than the 2% of patients in this cohort. By comparison,
up to 50% of schizophrenia patients are on polypharmacy (31)
despite the lack of compelling evidence for its efficacy (32). A
high polypharmacy rate therefore may therefore represent a gap
between treatment guidelines and implementation.
The single biggest barrier to clozapine utilization is probably
administrative burden associated with patient monitoring (33).
A mental health nurse we interviewed stated that a brand name
manufacturer of clozapine relieves some of the administrative
burdens by monitoring the patients’ blood test results for signs
of neutropenia. Patient refusal to initiate (or continue) clozapine
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upon hospital discharge at 19 to 40 percent (29, 51, 52). These
are consistent with our finding that polypharmacy is more
prevalent than treatment with clozapine. Finally, our data did
not include mortality—this may have contributed to the low
re-hospitalization rate.
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submitted version.
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